# SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

> **NCT02299999** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 1460 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** AZD2014
- **DRUG:** AZD4547
- **DRUG:** AZD5363
- **DRUG:** AZD8931
- **DRUG:** Selumetinib
- **DRUG:** Vandetanib
- **DRUG:** Bicalutamide
- **DRUG:** Olaparib
- **DRUG:** Anthracyclines
- **DRUG:** Taxanes
- **DRUG:** cyclophosphamide
- **DRUG:** DNA intercalators
- **DRUG:** Methotrexate
- **DRUG:** vinca alkaloids
- **DRUG:** Platinum based chemotherapies
- **DRUG:** Bevacizumab
- **DRUG:** Mitomycin C
- **DRUG:** Eribulin
- **DRUG:** MEDI4736

## Key facts

- **NCT ID:** NCT02299999
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-04-07
- **Primary completion:** 2022-12
- **Final completion:** 2025-12
- **Target enrollment:** 1460 (ACTUAL)
- **Last updated:** 2025-01-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02299999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02299999, "SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT02299999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*